Anti-CD33 chimeric antigen receptor T cell therapy - Intrexon/ZIOPHARM

Drug Profile

Anti-CD33 chimeric antigen receptor T cell therapy - Intrexon/ZIOPHARM

Alternative Names: Anti-CD33 chimeric antigen receptor T cell therapy - ZIOPHARM/Intrexon

Latest Information Update: 02 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intrexon Corporation; ZIOPHARM Oncology
  • Developer University of Texas M. D. Anderson Cancer Center; ZIOPHARM Oncology
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia

Most Recent Events

  • 09 Dec 2017 Pharmacodynamics data from a preclinical trial in acute myeloid leukaemia presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)
  • 04 Aug 2017 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (Parenteral) (NCT03126864)
  • 02 May 2017 The US FDA accepts an IND application for Acute myeloid leukaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top